These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 27179038)

  • 21. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
    Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
    Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
    Sharpe R; Pearson A; Herrera-Abreu MT; Johnson D; Mackay A; Welti JC; Natrajan R; Reynolds AR; Reis-Filho JS; Ashworth A; Turner NC
    Clin Cancer Res; 2011 Aug; 17(16):5275-86. PubMed ID: 21712446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
    Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
    Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
    Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
    Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
    J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Primary Drug Resistance in
    Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
    Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
    [No Abstract]   [Full Text] [Related]  

  • 38. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
    Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
    Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Grünewald S; Politz O; Bender S; Héroult M; Lustig K; Thuss U; Kneip C; Kopitz C; Zopf D; Collin MP; Boemer U; Ince S; Ellinghaus P; Mumberg D; Hess-Stumpp H; Ziegelbauer K
    Int J Cancer; 2019 Sep; 145(5):1346-1357. PubMed ID: 30807645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
    Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.